Relationship between casual serum triglyceride levels and the development of hypertension in Japanese.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
14
11
2020
medline:
16
10
2021
entrez:
13
11
2020
Statut:
ppublish
Résumé
The purpose of the present study was to investigate the effects of serum triglyceride levels on the risk of new-onset hypertension in Japanese. Five thousand nine hundred and thirty-three Japanese workers without hypertension at baseline, who participated in medical check-ups from 2006 to 2018, were followed retrospectively. The participants were divided into quartiles of casual serum triglyceride levels and were followed from the first to last visit of the study period. The outcome was development of hypertension. Risk estimates were computed using Cox's proportional hazards model. During the follow-up period (average: 6.7 years), 946 individuals developed hypertension. The crude incidence rates of hypertension (per 1000 person-years) increased with rising serum triglyceride levels: 10.1 for quartile 1 (<0.76 mmol/l), 19.6 for quartile 2 (0.76-1.17 mmol/l), 26.0 for quartile 3 (1.18-1.84 mmol/l), and 36.5 for quartile 4 (>1.84 mmol/l) (P < 0.0001 for trend). These associations remained significant even after adjustment for other risk factors: the multivariable-adjusted hazard ratio was 1.29 (1.01-1.66) for the second quartile, 1.27 (0.99-1.63) for the third quartile, and 1.39 (1.09-1.77) for the highest quartile compared with the lowest. There were comparable effects of serum triglyceride levels for incidence of hypertension between subgroups defined by sex, obesity, and diabetes (all P > 0.1 for interaction), whereas stronger associations were observed for participants under 40 years of age than for those aged 40 or above (P = 0.002 for interaction). Serum triglyceride levels were significantly associated with development of hypertension in a Japanese worksite population.
Identifiants
pubmed: 33186317
pii: 00004872-202104000-00014
doi: 10.1097/HJH.0000000000002693
doi:
Substances chimiques
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
677-682Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
World Health Organization. Fact-sheets of cardiovascular disease. Available at: http://www.who.int/news-room/fact-sheets/detail/hypetension. [Accessed 22 March 2020]
Mancia G, Facchetti R, Bombelli M, Friz HP, Grassi G, Giannattasio C, Sega R. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA Population. Hypertension 2005; 45:1072–1077.
Bombelli M, Toso E, Peronio M, Fodri D, Volpe M, Brambilla G, et al. The Pamela Study: main findings and perspectives. Curr Hypertens Rep 2013; 15:238–243.
Cicero AF, Rosticci M, Baronio C, Morbini M, Parini A, Grandi E, et al. Brisighella Heart Study Group. Serum LDL cholesterol levels and new onset of arterial hypertension: an 8-year follow-up. Eur J Clin Invest 2014; 44 (10):926–932.
Cicero AF, Fogacci F, Giovannini M, Grandi E, D’Addato S, Borghi C. Brisighella Heart Study group. Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension: data from the Brisighella Heart Study. J Hypertens 2019; 37:728–731.
Borghi C, Cicero AF, Saragoni S, Buda S, Cristofori C, Lilli P, Degli Esposti L. Rate of control of LDL cholesterol and incident hypertension requiring antihypertensive treatment in hypercholesterolemic subjects in daily clinical practice. Ann Med 2014; 46:97–102.
Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49:792–798.
Laaksonen DE, Niskanen L, Nyyssonen K, Lakka TA, Laukkanen JA, Salonen JT. Dyslipidemia as a predictor of hypertension in middle-aged men. Eur Heart J 2008; 29:2561–2568.
Hoffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension. Arch Intern Med 1996; 156:1994–2000.
Ding C, Yang Z, Wang S, Sun F, Zhan S. The association of metabolic syndrome with incident hypertension, type 2 diabetes mellitus and chronic kidney disease: a cohort study. Endocrine 2018; 60:282–291.
Paynter NP, Sesso HD, Conen D, Otvos JD, Mora S. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin Chem 2011; 57:1178–1187.
Sanchez-Inigo L, Navarro-Gonzalez D, Pastrana-Delgado J, Fernandez-Montero A, Alfredo Martinez J. Association of triglycerides and new lipid markers with the incidence of hypertension in a Spanish cohort. J Hypertens 2016; 34:1257–1265.
Tohidi M, Hatami M, Hadaegh F, Azizi F. Triglycerides and triglycerides to high-density lipoprotein cholesterol ratio are strong predictors of incident hypertension in Middle Eastern women. J Hum Hypertens 2012; 26:525–532.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849–1861.
Koh KK, Ahn JY, Quon MJ, Kim J, Han SH, Lee Y, Shin EK. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 2006; 29:195–201.
Kim J, Tsujino T, Fujioka Y, Saito K, Yokoyama M. Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res 2003; 26:307–313.
Ishikawa T, Obara T, Kataoka H, Hanazawa T, Tanaka K, Shibamiya T, et al. Blood pressure lowering effect of fenofibrate evaluated by home blood pressure. Ther Res 2007; 28:1853–1862.
Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Nephrol 2009; 4:1302–1311.
Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study. Daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49:40–47.
Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah. Hypertension 1991; 17:969–976.
Hirano T. Hypertriglyceridemia: concept and clinical signficance. Nippon Rinsho 2013; 71 (9):1519–1527.
Kume N, Kita T. Apoptosis of vascular cells by oxidized LDL. Involvement of caspases and LOX-1 and its implication in atherosclerotic plaque rupture. Circ Res 2004; 94:269–270.
Goto K, Ohtsubo T, Kitazono T. Endothelium-dependent hyperpolarization (EDH) in hypertension: the role of endothelial ion channels. Int J Mol Sci 2018; 19:315.
Vigili S, Puato M, Kiwanuka E, Prato S, Pauletto P, Pasini L, et al. Elevated non-esterified fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels. Atherosclerosis 2003; 169:147–153.
Hirano T, Oi K, Sakai S, Kashiwazaki K, Adachi M, Yoshino G. High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. Atherosclerosis 1998; 141:77–85.
Johnson RK, Appel LJ, Brands M, Howard BV, Lefevre M, Sacks F, et al. Dietary sugar intake and cardiovascular health. A scientific statement from the American Heart Association. Circulation 2009; 120:1011–1020.